Neuroblastoma: open trials in Israel

4 open trials have a site in Israel. Registry data; only the trial team decides who can take part.

NCT06395103
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Rambam Health Care Campus-Pediatric Hemato-Oncology ( Site 1674), Haifa · Sheba Medical Center ( Site 1675), Ramat Gan
Registry updated 2026-10-30
NCT07537400
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
Trial Treatment · Phase 2 · Shaare Zedek Medical Center
Shaare Zedek Medical Center, Jerusalem
Registry updated 2026-09-17
NCT05296564
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Trial Treatment · Phase 1/2 · Hadassah Medical Organization
Hadassah Medical Organization, Jerusalem
Registry updated 2025-10-02
NCT04221035
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Trial Treatment · Phase 3 · Gustave Roussy, Cancer Campus, Grand Paris
Rambam Medical Center, Haifa
Registry updated 2025-06-26

This page is not medical advice. Talk to your doctor before contacting a trial.

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)